Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(3.22) per share which missed the analyst consensus estimate of $(0.85) by 278.82 percent. This is a 75.27 percent increase over losses of $(13.02) per share from the same period last year. The company reported quarterly sales of $37.32 million which missed the analyst consensus estimate of $47.06 million by 20.69 percent. This is a 9.54 percent increase over sales of $34.07 million the same period last year.